TCR2 Therapeutics Inc. Common Stock (TCRR)

TCRR was delisted on the 31st of May, 2023.

• Market cap: $58.1M
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: TCR2 Therapeutics Inc is a clinical-stage cell therapy company. It is engaged in developing a pipeline of novel T cell therapies for cancer patients suffering from solid tumors by powering the T cell receptor (TCR) with its proprietary, first-in-class TCR Fusion Construct T cells (TRuC-T cells). The company's TRuC-T cells specifically recognize and kill cancer cells by harnessing the entire TCR signaling complex, independent of human leukocyte antigens, which are effective in patients with solid tumors.

Employees: 58